The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management

New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management

May 8, 2019 • By Kelly Tyrrell

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The process included use of a methodology called Grading of Recommendations Assessment, Development and Evaluation (GRADE), which was used to rate the quality of available evidence as high, moderate, low or very low, relative to the patient/population, intervention, comparison and outcomes (PICO) questions the team derived.

You Might Also Like
  • Shared Decision Making, Good Disease Control Are Key Components of JIA Management
  • Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes
  • Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
Explore This Issue
June 2019
Also By This Author
  • 3 Ways the ACR Helps Practices Thrive

“The main advantage [of GRADE] over the RAND methodology, used previously, is that it standardizes the process of moving from evidence to recommendations, leading to greater transparency around the process,” says Sarah Ringold, MD, MS, assistant professor of rheumatology at Seattle Children’s Hospital and a co-author of the guideline. Dr. Ringold also led the development of a new guideline for other aspects of JIA, including polyarthritis, sacroiliitis and enthesitis.3,4 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Ophthalmic Monitoring
Among the strongest recommendations in the new JIA-associated uveitis guideline are those that involve ophthalmic monitoring of patients with JIA, particularly those at risk of developing or already diagnosed with uveitis. This, the authors say, is because the high risk of ocular complications that can lead to vision loss is high, but the risk of complications from ophthalmic exams is low.

These recommendations are included despite the fact that frequent monitoring can create strain for families.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The treatment of the disease is often a bigger stressor for children than the disease itself,” says Dr. Holland, who with Dr. Angeles-Han and colleagues published a paper in the American Journal of Ophthalmology in 2018 describing the psychosocial elements for managing chronic anterior uveitis.5

However, says Dr. Angeles-Han, “In general, families agreed that scheduled ophthalmology visits for screening or monitoring of uveitis was important to achieve the most optimal visual outcomes.”

Guideline Objectives & Recommendations
Overall, the guideline team found a scarcity of good evidence in the literature, much of it rated low quality by the GRADE system, so the team developed its recommendations based on a combination of the best available data and consensus expert opinion. The guideline establishes terms, definitions and medication interventions, as well as critical outcomes for screening, monitoring and treatment. These include new diagnosis, loss of control of uveitis and side effects of systemic treatment.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Recommendations include:

  • Conditional recommendation for ophthalmic screening every three months for children and adolescents with JIA at high risk for uveitis;
  • Conditional recommendation to use topical glucocorticoids for short-term control rather than systemic glucocorticoids in children with JIA and active chronic anterior uveitis; and
  • Strong recommendation for ophthalmic monitoring within one month of a change in glucocorticoids in children and adolescents with JIA and controlled uveitis who are tapering or discontinuing topical glucocorticoids.

(Editor’s note: See the table below for all the recommendations.)

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Guidelines, Systemic Inflammatory Syndromes Tagged With: JIA-associated uveitis guideline, juvenile idiopathic arthritis (JIA), UveitisIssue: June 2019

You Might Also Like:
  • Shared Decision Making, Good Disease Control Are Key Components of JIA Management
  • Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes
  • Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
  • Adalimumab + Methotrexate Effective for Uveitis in JIA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)